好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Safety and Effectiveness of Lacosamide as Adjunctive Treatment for Partial-onset Seizures (POS) in Hispanic/Latino Patients from Mexico: Post-hoc Analysis of an Open-label Trial
Epilepsy/Clinical Neurophysiology (EEG)
(-)
265
Authors/Disclosures
Hugo Ceja
PRESENTER
No disclosure on file
No disclosure on file
Antonio Escartin, MD (Hospital Sant Pau) No disclosure on file
William J. Byrnes, MD No disclosure on file
Frank Tennigkeit, PhD (UCB Biosciences GmbH) Dr. Tennigkeit has received personal compensation for serving as an employee of UCB Biosciences. Dr. Tennigkeit has stock in UCB Biosciences.
Simon Borghs No disclosure on file
Cindy McShea No disclosure on file
No disclosure on file
Marc De Backer, MD, FBCPM, MBA No disclosure on file
Imane Kermadi-Wild, PhD, MBA (UCB) No disclosure on file
Josep O. Dalmau, MD, PhD, FAAN Dr. Dalmau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astellas Research Institute of America. Dr. Dalmau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen Research & Development . Dr. Dalmau has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for 好色先生. An immediate family member of Dr. Dalmau has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Dalmau has received research support from Sage Therapeutics. The institution of Dr. Dalmau has received research support from Edmond J.Safra Foundation . The institution of Dr. Dalmau has received research support from La Caixa Foundation. The institution of Dr. Dalmau has received research support from Spanish Ministry of Health (ISCIII). The institution of Dr. Dalmau has received research support from Euroimmun, Inc. Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care.